BioAtla Statistics
Total Valuation
BioAtla has a market cap or net worth of $11.15 million. The enterprise value is $10.23 million.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAtla has 82.85 million shares outstanding. The number of shares has increased by 21.11% in one year.
| Current Share Class | 82.85M |
| Shares Outstanding | 82.85M |
| Shares Change (YoY) | +21.11% |
| Shares Change (QoQ) | +1.81% |
| Owned by Insiders (%) | 7.30% |
| Owned by Institutions (%) | 11.06% |
| Float | 69.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.58 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.37
| Current Ratio | 0.37 |
| Quick Ratio | 0.32 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -111.90% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 732.70% |
| Weighted Average Cost of Capital (WACC) | 7.00% |
| Revenue Per Employee | $32,787 |
| Profits Per Employee | -$977,164 |
| Employee Count | 61 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.19% in the last 52 weeks. The beta is 1.21, so BioAtla's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | -61.19% |
| 50-Day Moving Average | 0.20 |
| 200-Day Moving Average | 0.49 |
| Relative Strength Index (RSI) | 37.34 |
| Average Volume (20 Days) | 1,255,707 |
Short Selling Information
The latest short interest is 1.92 million, so 2.32% of the outstanding shares have been sold short.
| Short Interest | 1.92M |
| Short Previous Month | 2.05M |
| Short % of Shares Out | 2.32% |
| Short % of Float | 2.78% |
| Short Ratio (days to cover) | 1.12 |
Income Statement
In the last 12 months, BioAtla had revenue of $2.00 million and -$59.61 million in losses. Loss per share was -$1.01.
| Revenue | 2.00M |
| Gross Profit | 2.00M |
| Operating Income | -59.31M |
| Pretax Income | -59.61M |
| Net Income | -59.61M |
| EBITDA | -58.93M |
| EBIT | -59.31M |
| Loss Per Share | -$1.01 |
Full Income StatementBalance Sheet
The company has $7.12 million in cash and $6.20 million in debt, with a net cash position of $918,000 or $0.01 per share.
| Cash & Cash Equivalents | 7.12M |
| Total Debt | 6.20M |
| Net Cash | 918,000 |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | -36.19M |
| Book Value Per Share | -0.61 |
| Working Capital | -13.91M |
Full Balance SheetCash Flow
| Operating Cash Flow | -48.20M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 373,000 |
| Net Borrowing | 7.13M |
| Free Cash Flow | -48.20M |
| FCF Per Share | -$0.58 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -2,965.25% |
| Pretax Margin | -2,980.35% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
